International Journal of Molecular Sciences (Apr 2021)

Insulin Signaling as a Therapeutic Target in Glaucomatous Neurodegeneration

  • Sara Al Hussein Al Awamlh,
  • Lauren K. Wareham,
  • Michael L. Risner,
  • David J. Calkins

DOI
https://doi.org/10.3390/ijms22094672
Journal volume & issue
Vol. 22, no. 9
p. 4672

Abstract

Read online

Glaucoma is a multifactorial disease that is conventionally managed with treatments to lower intraocular pressure (IOP). Despite these efforts, many patients continue to lose their vision. The degeneration of retinal ganglion cells (RGCs) and their axons in the optic tract that characterizes glaucoma is similar to neurodegeneration in other age-related disorders of the central nervous system (CNS). Identifying the different molecular signaling pathways that contribute to early neuronal dysfunction can be utilized for neuroprotective strategies that prevent degeneration. The discovery of insulin and its receptor in the CNS and retina led to exploration of the role of insulin signaling in the CNS. Historically, insulin was considered a peripherally secreted hormone that regulated glucose homeostasis, with no obvious roles in the CNS. However, a growing number of pre-clinical and clinical studies have demonstrated the potential of modulating insulin signaling in the treatment of neurodegenerative diseases. This review will highlight the role that insulin signaling plays in RGC neurodegeneration. We will focus on how this pathway can be therapeutically targeted to promote RGC axon survival and preserve vision.

Keywords